Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1-9
机构:[1]Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.[2]Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: baichunmei1964@163.com.[3]Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. Electronic address: jmxu2003@yahoo.com.[4]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: linshenpku@163.com.[5]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.[6]Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.[7]Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[8]National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.[9]Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.[10]Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.[11]Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.浙江大学医学院附属第一医院[12]Department of General Surgery, Zhongshan Hospital of Fudan University, Shanghai, China.[13]Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.[14]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.华中科技大学同济医学院附属同济医院[15]Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan.[16]Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.[17]Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China.[18]Department of Clinical and Regulatory Affairs, HUTCHMED, Shanghai, China.
第一作者机构:[1]Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
推荐引用方式(GB/T 7714):
Li Jiarui,Cheng Yuejuan,Bai Chunmei,et al.Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1-9[J].European journal of cancer (Oxford, England : 1990).2022,doi:10.1016/j.ejca.2022.10.001.
APA:
Li Jiarui,Cheng Yuejuan,Bai Chunmei,Xu Jianming,Shen Lin...&Su Weiguo.(2022).Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1-9.European journal of cancer (Oxford, England : 1990),,
MLA:
Li Jiarui,et al."Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1-9".European journal of cancer (Oxford, England : 1990) .(2022)